MEDICAL EQUIPMENT MANUFACTURER C L O S E D S Y S T E M D R U G T R A N S F E R D E V I C E • A new material for a seal inside the next generation of closed system drug transfer device • Compliance with stringent regulatory standards: • Biocompatibility to ISO10993 • USP VI compliance • Provided regulatory support services and expertise throughout extensive medical approval process • Provided a custom formulation compliant with the highest healthcare regulatory standards • Enabled material to be manufactured and shipped globally Custom Versalloy™ HC 9220-90 Formulation KEY REQUIREMENTS WHY AVIENT?

SECURITY EQUIPMENT MANUFACTURER B O D Y S C A N N E R • Replace PMMA based radome material • Consistent dielectric performance across large sheet/surface area (4mm thick, 2m high) • Ultra low losses • No defects across full surface area • High resolution imaging to show small illegal objects • Formulated a custom material to match customer requirements • Reduced dielectric loss to 0.0009 • Improved image quality of body scanner with uniform dielectric performance and exceptionally low losses • Enabled scan time of 2 seconds and person throughput of 400 persons per hour, compared to 100 person throughput of conventional devices PREPERM™ PPE 260 Formulation KEY REQUIREMENTS WHY AVIENT?

Home printer OEM HOME PRINTER OEM R E C Y C L E D H I P S I N J E C T I O N C O V E R O F P R I N T E R • Provide PCR-based colorants for a more sustainable solution • Meet both color and mechanical requirements in PCR materials • Offer user-friendly PCR + Colorants solution to address the batch variance problem of PCR in an economical way • Offered revolutionary supply model of PCR + Colorants, ensuring precise quality and color • Helped customers solve the batch variance problem of PCR in a digital way and shortened the color-matching time with PCR Color Prediction Service • Provided on-site technical support to customer Rejoin PCR Colorants KEY REQUIREMENTS WHY AVIENT?

Avient does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for Adjusted EBITDA and Adjusted Earnings Per Share, to the most comparable GAAP financial measures on a forward-looking basis because Avient is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort.

As the year progressed, economic outlook showed signs of improvement and destocking dynamics subsided, which helped increase market demand.

Avient does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for Adjusted EBITDA, Adjusted Earnings Per Share and Free Cash Flow to the most comparable GAAP financial measures on a forward-looking basis because Avient is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. PRIOR YEAR $790 $710 2022 2023 $107 $112 2022 2023 Sales Adjusted EBITDA $0.42 $0.47 2022 PF 2023 - 10% + 5% + 12% Sales Adjusted EBITDA Adjusted EPS 16 $112 $500 $0.47 Q4 AND FULL YEAR 2023 GUIDANCE $710 $3,130 Sales Adjusted EBITDA Adjusted EPS 17 (in millions) (in millions) Guidance: Free Cash Flow $180 $180 Prior Guidance Guidance FREE CASH FLOW & INCREASED DIVIDEND 13th Consecutive Dividend Increase 0.16 0.26 0.42 0.58 0.79 0.85 0.99 1.03 2011 2013 2015 2017 2019 2021 2023 2024 S U S TAI NABI L I T Y DAY RE CAP SUSTAINABILITY AS A GROWTH DRIVERLONG-TERM REVENUE GROWTH DRIVERS 60%+ Key Growth Drivers Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other (GDP Growth) Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other (GDP growth) 0–2% Avient 6% SUSTAINABILITY TRENDS DRIVE LONG-TERM GROWTH 8-12% Long Term Growth 50 90 2022 2030 Medical Plastics Market Size (in $Billions) 2020 2030 Recycled Plastics Virgin Plastics Growing Demand for Recycled Content Avient Sustainable Solutions 46 2023 2032 Global Offshore Annual Wind Installations (in Gigawatts) Sources: McKinsey, Bloomberg, Grand View Research SUSTAINABILITY TRENDS DRIVE LONG-TERM GROWTH 21 • Transformative acquisitions combined with divestitures of more cyclical businesses have improved margins over 400 bps since 2018 • 20% long-term margin goal to be driven by key growth drivers, with sustainable solutions playing a meaningful role 5.4% 11.5% 2006 2018 2023E Recovery Growth Drivers Strategic Objective 20%+ +1%+ +3%+ ADJUSTED EBITDA MARGIN EXPANSION 22 • 6% annualized long-term sales growth leveraging sustainable solutions, composites, healthcare, and emerging regions • Expand EBITDA margins to 20% • Deliver annual EBITDA and EPS growth of 10% and 15% • Maintain asset-light, 80% free cash flow conversion profile and be valued as a specialty formulator • Continue fostering our Great Place to Work® culture CREATING A WORLD-CLASS SUSTAINABLE ORGANIZATION 23 PEER COMPARISONS AVIENT IS ASSET LIGHT Capex / Revenue 2023E (%) Avient Specialty Other Specialty / Note: Avient reflects 2023 estimated revenue of $3,130 and estimated run-rate CAPEX of $110M. 26 3.5 1.8 2.7 3.1 3.3 3.7 3.0 3.7 4.7 4.8 6.8 6.8 8.7 11.1 Av ie nt AV PM FM N C FREE CASH FLOW CONVERSION Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA.

Avient Corporation investor events and presentations offer investors, potential investors, analysts and the financial press the opportunity to learn more about our performance as a company, our outlook and our strategy.

Avient Corporation investor events and presentations offer investors, potential investors, analysts and the financial press the opportunity to learn more about our performance as a company, our outlook and our strategy.

Avient Corporation investor events and presentations offer investors, potential investors, analysts and the financial press the opportunity to learn more about our performance as a company, our outlook and our strategy.

Avient Corporation investor events and presentations offer investors, potential investors, analysts and the financial press the opportunity to learn more about our performance as a company, our outlook and our strategy.